Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination

Background: EXTEND (NCT01797965), an open-label extension study, evaluated the safety and efficacy of daclizumab beta in participants with relapsing multiple sclerosis (MS) who had completed the randomized DECIDE study. Methods: Eligible participants who received either daclizumab beta or interferon beta-1a in DECIDE received daclizumab beta 150 mg subcutaneously every 4 weeks for up to 5 years in EXTEND, followed by 24 weeks of post-dosing follow-up. Safety and tolerability were evaluated, as were clinical efficacy and magnetic resonance imaging (MRI). EXTEND was terminated ahead of schedule by the sponsors. Results: The total safety population (N = 1203) received at least one dose of daclizumab beta in EXTEND. In the DECIDE and EXTEND combined periods, the median number of doses of daclizumab beta was 53; median time on treatment was 196 weeks. By 24 September 2018, the end of the study, 110/1203 (9%) participants had completed the protocol-specified treatment period and 1101/1203 (92%) had experienced an adverse event (AE). The most commonly reported AEs were MS relapse, nasopharyngitis, and upper respiratory tract infection. Hepatic events (18%), cutaneous events (45%), and infections (62%) were common treatment-related AEs. The incidence of serious AEs was 29%, most commonly MS relapse and infections. The incidence of immune-mediated disorders was 2%; three of seven were encephalitis. Two of six deaths were considered treatment related. In participants who received continuous daclizumab beta throughout DECIDE and EXTEND, the treatment effects on clinical and MRI outcomes were maintained for up to 6 years. Conclusion: Results from the combined DECIDE-EXTEND study elucidate outcomes of longer-term treatment with daclizumab beta in the clinical trial setting and underscore the importance of pharmacovigilance with immunomodulatory therapies in the real-world setting.

[1]  S. Cohan,et al.  Daclizumab: Mechanisms of Action, Therapeutic Efficacy, Adverse Events and Its Uncovering the Potential Role of Innate Immune System Recruitment as a Treatment Strategy for Relapsing Multiple Sclerosis , 2019, Biomedicines.

[2]  H. Wiendl,et al.  Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta , 2018, Multiple sclerosis.

[3]  L. Kappos,et al.  No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study , 2017, Multiple sclerosis.

[4]  L. Kappos,et al.  Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE , 2017, Multiple sclerosis.

[5]  J. Rose,et al.  Daclizumab: Development, Clinical Trials, and Practical Aspects of Use in Multiple Sclerosis , 2017, Neurotherapeutics.

[6]  M. Vachová,et al.  Daclizumab high-yield process in the treatment of relapsing–remitting multiple sclerosis , 2017, Therapeutic advances in neurological disorders.

[7]  I. Nestorov,et al.  Population PK-PD analyses of CD25 occupancy, CD56bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis. , 2016, British journal of clinical pharmacology.

[8]  S. Cohan.  Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis , 2016, Biologics : targets & therapy.

[9]  L. Kappos,et al.  Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. , 2016, Multiple sclerosis and related disorders.

[10]  X. Montalban,et al.  Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study , 2016, BMC Neurology.

[11]  C. Blank.  FDA approves Zinbryta to treat multiple sclerosis , 2016 .

[12]  M. Sweetser,et al.  Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis , 2016, Advances in Therapy.

[13]  H. Hartung,et al.  Disease-modifying therapies and infectious risks in multiple sclerosis , 2016, Nature Reviews Neurology.

[14]  M. Raffeld,et al.  Cutaneous adverse events in multiple sclerosis patients treated with daclizumab , 2016, Neurology.

[15]  D. Arnold,et al.  Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. , 2015, The New England journal of medicine.

[16]  K. Selmaj,et al.  CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[17]  X. Montalban,et al.  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial , 2014, The Lancet Neurology.

[18]  A. Venkatesan,et al.  Infections and multiple sclerosis , 2014, Handbook of clinical neurology.

[19]  Gavin Giovannoni,et al.  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[20]  T. Waldmann,et al.  Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. , 2009, Archives of neurology.